DUALITYBIO-B (09606) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results and Review Final Dividend Proposal

Bulletin Express

Yesterday

Duality Biotherapeutics, Inc. (stock code: 09606, abbreviation: DUALITYBIO-B) has scheduled a board meeting for 23 March 2026. According to the company’s announcement, directors will consider and approve the consolidated financial results for the year ended 31 December 2025 and evaluate whether to recommend a final dividend.

The board currently comprises three executive directors—Dr. Zhu Zhongyuan (Chairman and CEO), Mr. Zhang Shaoren, and Ms. Si Wen—two non-executive directors—Mr. Cai Zhiyang and Dr. Yu Tao—and three independent non-executive directors—Mr. Xie Dong, Mr. Gao Fengyong, and Ms. Chuai Shuyin.

The company will release its audited annual results and any dividend recommendation following board approval. The announcement was released in Hong Kong on 11 March 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1190504580"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1190504580\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1190504580?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-11 16:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190504580","market":"hk","top_or_hot":-1,"title":"DUALITYBIO-B (09606) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results and Review Final Dividend Proposal","media":"Bulletin Express","content":"<p>Duality Biotherapeutics, Inc. (stock code: 09606, abbreviation: DUALITYBIO-B) has scheduled a board meeting for 23 March 2026. According to the company’s announcement, directors will consider and approve the consolidated financial results for the year ended 31 December 2025 and evaluate whether to recommend a final dividend.</p>\n<p>The board currently comprises three executive directors—Dr. Zhu Zhongyuan (Chairman and CEO), Mr. Zhang Shaoren, and Ms. Si Wen—two non-executive directors—Mr. Cai Zhiyang and Dr. Yu Tao—and three independent non-executive directors—Mr. Xie Dong, Mr. Gao Fengyong, and Ms. Chuai Shuyin.</p>\n<p>The company will release its audited annual results and any dividend recommendation following board approval. The announcement was released in Hong Kong on 11 March 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DUALITYBIO-B (09606) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results and Review Final Dividend Proposal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDUALITYBIO-B (09606) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results and Review Final Dividend Proposal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-11 16:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Duality Biotherapeutics, Inc. (stock code: 09606, abbreviation: DUALITYBIO-B) has scheduled a board meeting for 23 March 2026. According to the company’s announcement, directors will consider and approve the consolidated financial results for the year ended 31 December 2025 and evaluate whether to recommend a final dividend.</p>\n<p>The board currently comprises three executive directors—Dr. Zhu Zhongyuan (Chairman and CEO), Mr. Zhang Shaoren, and Ms. Si Wen—two non-executive directors—Mr. Cai Zhiyang and Dr. Yu Tao—and three independent non-executive directors—Mr. Xie Dong, Mr. Gao Fengyong, and Ms. Chuai Shuyin.</p>\n<p>The company will release its audited annual results and any dividend recommendation following board approval. The announcement was released in Hong Kong on 11 March 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1190504580","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190504580","pubTimestamp":1773218620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Duality Biotherapeutics, Inc. (stock code: 09606, abbreviation: DUALITYBIO-B) has scheduled a board meeting for 23 March 2026. According to the company’s announcement, directors will consider and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"DUALITYBIO-B(09606)定于2026年3月23日召开董事会批准2025财年业绩并审阅末期股息建议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"Duality Biotherapeutics, Inc. (stock code: 09606, abbreviation: DUALITYBIO-B) has scheduled a board meeting for 23 March 2026. According to the company’s announcement, directors will consider and approve the consolidated financial results for the year ended 31 December 2025 and evaluate whether to recommend a final dividend.\nThe board currently comprises three executive directors—Dr. Zhu Zhongyuan (Chairman and CEO), Mr. Zhang Shaoren, and Ms. Si Wen—two non-executive directors—Mr. Cai Zhiyang and Dr. Yu Tao—and three independent non-executive directors—Mr. Xie Dong, Mr. Gao Fengyong, and Ms. Chuai Shuyin.\nThe company will release its audited annual results and any dividend recommendation following board approval. The announcement was released in Hong Kong on 11 March 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}